Mammalian target of rapamycin inhibitors induce tumor cell apoptosis in vivo primarily by inhibiting VEGF expression and angiogenesis

Journal of Oncology

Volumn , Issue , 2013, Pages

  Frost, Patrick ^a,b   Berlanger, Eileen ^a   Mysore, Veena ^a   Hoang, Bao ^a,b   Shi, Yijiang ^a,b   Gera, Joseph ^a,b   Lichtenstein, Alan ^a,b  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN P27; RAPALOG; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTERNAL RIBOSOME ENTRY SITE; MALE; MOUSE; NONHUMAN; OPEN READING FRAME; PROTEIN EXPRESSION;

EID: 84875585306     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2013/897025     Document Type: Article

References (32)

1. Atkins M. B., Hidalgo M., Stadler W. M., Logan T. F., Dutcher J. P., Hudes G. R., Park Y., Liou S. H., Marshall B., Boni J. P., Dukart G., Sherman M. L., Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. Journal of Clinical Oncology 2004 22 5 909 918 2-s2.0-1542398693 10.1200/JCO.2004.08.185 (Pubitemid 41103603)
2. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., Staroslawska E., Sosman J., McDermott D., Bodrogi I., Kovacevic Z., Lesovoy V., Schmidt-Wolf I. G., Barbarash O., Gokmen E., O'Toole T., Lustgarten S., Moore L., Motzer R. J., Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. The New England Journal of Medicine 2007 356 2271 2281 (Pubitemid 46849157)
3. Younes A., Samad N., Utility of mTOR inhibition in hematologic malignancies. Oncologist 2011 16 6 730 741 2-s2.0-79959610128 10.1634/theoncologist.2010-0318
4. Raje N., Kumar S., Hideshima T., Ishitsuka K., Chauhan D., Mitsiades C., Podar K., Le Gouill S., Richardson P., Munshi N. C., Stirling D. I., Antin J. H., Anderson K. C., Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 2004 104 13 4188 4193 2-s2.0-10244260355 10.1182/blood-2004-06-2281 (Pubitemid 39620173)
5. Zangari M., Cavallo F., Tricot G., Farnesyltransferase inhibitors and rapamycin in the treatment of multiple myeloma. Current Pharmaceutical Biotechnology 2006 7 6 449 453 2-s2.0-33845898823 10.2174/138920106779116838 (Pubitemid 46017536)
6. Frost P., Moatamed F., Hoang B., Shi Y., Gera J., Yan H., Frost P., Gibbons J., Lichtenstein A., In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 2004 104 13 4181 4187 2-s2.0-10244229652 10.1182/blood-2004-03-1153 (Pubitemid 39620172)
7. Strömberg T., Dimberg A., Hammarberg A., Carlson K., Österborg A., Nilsson K., Jernberg-Wiklund H., Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 2004 103 8 3138 3147 2-s2.0-17444440115 10.1182/blood-2003-05-1543 (Pubitemid 38451692)
8. Yan H., Frost P., Shi Y., Hoang B., Sharma S., Fisher M., Gera J., Lichtenstein A., Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Research 2006 66 4 2305 2313 2-s2.0-33644516582 10.1158/0008-5472.CAN-05-2447
9. Frost P., Shi Y., Hoang B., Lichtenstein A., AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells. Oncogene 2007 26 16 2255 2262 2-s2.0-34147104488 10.1038/sj.onc.1210019 (Pubitemid 46572812)
10. Ikezoe T., Nishioka C., Tasaka T., Yang Y., Komatsu N., Togitani K., Koeffler H. P., Taguchi H., The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamcycin signaling. Molecular Cancer Therapeutics 2006 5 10 2522 2530 2-s2.0-33750483896 10.1158/1535-7163.MCT-06-0071 (Pubitemid 44650916)
11. Shi Y., Hsu J. H., Hu L., Gera J., Lichtenstein A., Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6. Journal of Biological Chemistry 2002 277 18 15712 15720 2-s2.0-0037013205 10.1074/jbc.M200043200 (Pubitemid 34967845)
12. Shi Y., Gera J., Hu L., Hsu J. H., Bookstein R., Li W., Lichtenstein A., Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Research 2002 62 17 5027 5034 2-s2.0-0036735346 (Pubitemid 34984430)
13. Witzig T. E., Geyer S. M., Ghobrial I., Inwards D. J., Fonseca R., Kurtin P., Ansell S. M., Luyun R., Flynn P. J., Morton R. F., Dakhil S. R., Gross H., Kaufmann S. H., Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. Journal of Clinical Oncology 2005 23 23 5347 5356 2-s2.0-23944481410 10.1200/JCO.2005.13.466 (Pubitemid 46206988)
14. Smith S. M., van Besien K., Karrison T., Dancey J., McLaughlin P., Younes A., Smith S., Stiff P., Lester E., Modi S., Doyle L. A., Vokes E. E., Pro B., Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: the University of Chicago phase II consortium. Journal of Clinical Oncology 2010 28 31 4740 4746 2-s2.0-78149239933 10.1200/JCO.2010.29.2813
15. Gera J. F., Mellinghoff I. K., Shi Y., Rettig M. B., Tran C., Hsu J. H., Sawyers C. L., Lichtenstein A. K., AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. Journal of Biological Chemistry 2004 279 4 2737 2746 2-s2.0-1642535431 10.1074/jbc.M309999200 (Pubitemid 38114263)
16. Kullmann M., Göpfert U., Siewe B., Hengst L., ELAV/Hu proteins inhibit p27 translation via an IRES element in the p27 5′UTR. Genes and Development 2002 16 23 3087 3099 2-s2.0-0036894711 10.1101/gad.248902 (Pubitemid 35424195)
17. Miskimins W. K., Wang G., Hawkinson M., Miskimins R., Control of cyclin-dependent kinase inhibitor p27 expression by cap-independent translation. Molecular and Cellular Biology 2001 21 15 4960 4967 2-s2.0-0034947868 10.1128/MCB.21.15.4960-4967.2001 (Pubitemid 32656394)
18. LeBlanc R., Catley L. P., Hideshima T., Lentzsch S., Mitsiades C. S., Mitsiades N., Neuberg D., Goloubeva O., Pien C. S., Adams J., Gupta D., Richardson P. G., Munshi N. C., Anderson K. C., Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Research 2002 62 17 4996 5000 2-s2.0-0036735298 (Pubitemid 34984425)
19. Neshat M. S., Mellinghoff I. K., Tran C., Stiles B., Thomas G., Petersen R., Frost P., Gibbons J. J., Wu H., Sawyers C. L., Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proceedings of the National Academy of Sciences of the United States of America 2001 98 18 10314 10319 2-s2.0-17944377486 10.1073/pnas.171076798 (Pubitemid 32803017)
20. Frost P., Shi Y., Hoang B., Gera J., Lichtenstein A., Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin. Molecular Cancer Therapeutics 2009 8 1 83 93 2-s2.0-58149490636 10.1158/1535-7163.MCT-08-0254
21. Ackler S., Xiao Y., Mitten M. J., Foster K., Oleksijew A., Refici M., Schlessinger S., Wang B., Chemburkar S. R., Bauch J., Tse C., Frost D. J., Fesik S. W., Rosenberg S. H., Elmore S. W., Shoemaker A. R., ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Molecular Cancer Therapeutics 2008 7 10 3265 3274 2-s2.0-55749084366 10.1158/1535-7163.MCT-08- 0268
22. Jiang H., Coleman J., Miskimins R., Srinivasan R., Miskimins W. K., Cap-independent translation through the p27 5′-UTR. Nucleic Acids Research 2007 35 14 4767 4778 2-s2.0-34547911389 10.1093/nar/gkm512 (Pubitemid 47250348)
23. Feldman M. E., Apsel B., Uotila A., Loewith R., Knight Z. A., Ruggero D., Shokat K. M., Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biology 2009 7 2, article e38 2-s2.0-65249156511 10.1371/journal.pbio.1000038
24. Yu K., Shi C., Toral-Barza L., Lucas J., Shor B., Kim J. E., Zhang W. G., Mahoney R., Gaydos C., Tardio L., Kim S. K., Conant R., Curran K., Kaplan J., Verheijen J., Ayral-Kaloustian S., Mansour T. S., Abraham R. T., Zask A., Gibbons J. J., Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Research 2010 70 2 621 631 2-s2.0-76549107351 10.1158/0008-5472.CAN-09-2340
25. Hoang B., Frost P., Shi Y., Belanger E., Benavides A., Pezeshkpour G., Cappia S., Guglielmelli T., Gera J., Lichtenstein A., Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 2010 116 22 4560 4568 2-s2.0-78649471733 10.1182/blood-2010-05-285726
26. Falcon B. L., Barr S., Gokhale P. C., Chou J., Fogarty J., Depeille P., Miglarese M., Epstein D. M., M D. M., Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Research 2011 71 5 1573 1583 2-s2.0-79952216582 10.1158/0008-5472.CAN-10-3126
27. Del Bufalo D., Ciuffreda L., Trisciuoglio D., Desideri M., Cognetti F., Zupi G., Milella M., Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Research 2006 66 11 5549 5554 2-s2.0-33745242315 10.1158/0008-5472.CAN-05-2825 (Pubitemid 43927103)
28. Xue Q., Hopkins B., Perruzzi C., Udayakumar D., Sherris D., Benjamin L. E., Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Research 2008 68 22 9551 9557 2-s2.0-56449087509 10.1158/0008-5472.CAN-08-2058
29. Chen W., Ma T., Shen X. N., Xia X. F., Xu G. D., Bai X. L., Liang T. B., Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway. Cancer Research 2012 72 1363 1372 10.1158/0008-5472.CAN-11-2684
30. Stein I., Itin A., Einat P., Skaliter R., Grossman Z., Keshet E., Translation of vascular endothelial growth factor mRNA by internal ribosome entry: implications for translation under hypoxia. Molecular and Cellular Biology 1998 18 6 3112 3119 2-s2.0-0031869662 (Pubitemid 28240484)
31. Bert A. G., Grépin R., Vadas M. A., Goodall G. J., Assessing IRES activity in the HIF-1 α and other cellular 5′ UTRs. RNA 2006 12 6 1074 1083 2-s2.0-33646884832 10.1261/rna.2320506 (Pubitemid 43788125)
32. Young R. M., Wang S. J., Gordan J. D., Ji X., Liebhaber S. A., Simon M. C., Hypoxia-mediated selective mRNA translation by an internal ribosome entry site-independent mechanism. Journal of Biological Chemistry 2008 283 24 16309 16319 2-s2.0-47749141892 10.1074/jbc.M710079200